Botanix at the Jefferies Healthcare Conference

Philadelphia PA and Sydney Australia, 6 June 2019: Medical dermatology company Botanix Pharmaceuticals (“Botanix” or “the Company”) is pleased to announce that its Founder and Executive Director, Matt Callahan, will be presenting the Company’s progress at the 2019 Jefferies Healthcare Conference in New York. Mr Callahan’s presentation is attached to this release.

Jefferies Group is the largest independent full-service global investment banking firm headquartered in the U.S. The conference features company presentations, thematic panel discussions, and one-on-one meetings. Last year, the event attracted more than 2,600 attendees from around the world.

Mr Callahan will provide an update on the progress of Botanix’s late stage clinical programs, including the acne study (Phase 2), atopic dermatitis study (Phase 2) and the psoriasis mechanism of action study (Phase 1b) which remain on track for data read outs in 3Q CY2019, 4Q CY2019 and 2Q CY2019, respectively. The conference will also allow Botanix to establish links with various investors and potential strategic partners.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12-week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical study in June 2018 with data read-out expected in Q3 2019. The BTX 1204 atopic dermatitis Phase 2 patient study is also underway with enrolment expected to be
completed in 3Q CY2019. Finally, Phase 1b BTX 1308 psoriasis mechanism of action study is nearing completion with data anticipated to be available in 2Q CY2019. Pipeline projects that leverage the anti-microbial properties of cannabidiol are also moving forward and are planned to enter the clinic in 2H 2019.

To learn more please visit: https://www.botanixpharma.com/

For more information, please contact:

**General enquiries**
Matt Callahan  
Botanix Pharmaceuticals  
Founder & Executive Director  
+1 215 767 4184  
mcallahan@botanixpharma.com

**Investor enquiries**
Joel Seah  
Vesparum Capital  
P: +61 3 8582 4800  
botenixpharma@vesparum.com

**Media enquiries**
Haley Chartres  
Hales² Communications  
P: +61 423 139 163  
haley@h-squared.com.au
Botanix Overview

Jefferies Healthcare Conference

June 2019
Botanix overview

Cannabinoid focused pharmaceutical company, with one of the world’s most advanced clinical pipelines, studying CBD in a range of inflammatory and antimicrobial applications

- **Multiple value inflection points**: Significant clinical inflection points from **completion of funded studies for acne, atopic dermatitis and psoriasis in 2019**

- **Growing data support**: Recent FDA approval of Epidiolex® **validates the safety profile and therapeutic potential of synthetic cannabidiol** as a novel therapeutic

- **Validation of pharma focus**: Investment in the sector is moving beyond plants – **Botanix is one of the world’s most advanced pharma-focused synthetic cannabinoid companies**

- **Technology driven**: Novel skin delivery technology, Permetrex™ is **proven to enhance delivery of cannabidiol** and provides a **novel IP position**

- **World class team**: Team has significant clinical, regulatory and commercial expertise and has advanced product candidates into Phase 2 studies within 24 months of commencement
Australian Stock Exchange (ASX) listed company showing stable share appreciation and a highly aligned Board and management team

### Corporate overview

### Trading information

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Share price (as at 5-Jun-2019)</td>
<td>A$0.100</td>
</tr>
<tr>
<td>52 week low / high</td>
<td>A$0.180 / A$0.069</td>
</tr>
<tr>
<td>Shares outstanding(^1)</td>
<td>765m</td>
</tr>
<tr>
<td>Market capitalisation(^1)</td>
<td>A$76.5m</td>
</tr>
<tr>
<td>Cash (as at 31-Mar-2019)</td>
<td>A$9.3m</td>
</tr>
<tr>
<td>Debt (as at 31-Mar-2019)</td>
<td>-</td>
</tr>
</tbody>
</table>

### Top shareholders (May 2019)

<table>
<thead>
<tr>
<th>Shareholder</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Callahan – Founder and Executive Director</td>
<td>9.2</td>
</tr>
<tr>
<td>Caperi Pty Ltd – Co-founder</td>
<td>9.2</td>
</tr>
<tr>
<td>Board and management (excl. shareholders above)</td>
<td>2.6</td>
</tr>
</tbody>
</table>

Source: IRESS

\(^1\) Excludes 53.2m options
Significant re-rating potential if data continues to be positive

Botanix has one of the most advanced CBD clinical programs globally, with potential for a significant value inflection points following multiple clinical study completions in 2019

Lead products: BTX 1503, BTX 1204, BTX 1308
Phase 2 acne, Phase 2 atopic dermatitis and Phase 1b psoriasis

Target population: 100m patients p.a.


CBD source: Synthetic (100% pure)
Manufactured at industrial scale, facilitates relatively lower COGS

Technology: Permetrex™ skin delivery platform

Pipeline products:
Multiple clinic-ready products which leverage published efficacy data and target attractive markets (e.g. antimicrobial markets worth >US$10bn p.a.)

Lead product: Epidiolex®
FDA Approved for Lennox-Gastaut / Dravet epilepsy

Target population: 43k patients p.a.


CBD source: Naturally extracted
Manufacturing scale up and quality variation challenges, leads to relatively higher COGS

Technology: None – oil based oral delivery

Pipeline products:
Focused on similar CNS markets as Epidiolex® (product cannibalisation risk) or niche markets; other than Rhett’s - in early clinical development with limited efficacy data published to date

Significant opportunity for value inflections following successful results

1. Bloomberg
2. GBI Research. Dermatology Therapeutics Market to 2018; American Academy of Dermatology; British Journal of Dermatology; Expert Review of Dermatology.
3. Symphony Health Solutions PHAST
5. Cowen analyst report February 2019

Botanix Overview – June 2019

www.botanixpharma.com
Our focus is on large markets that are poised for growth

Global medical dermatology market is expected to grow to US$43bn by 2024\(^1\)

**2017 global dermatology market\(^1\)**

- US$22bn sales
  - Acne: 1.5
  - Psoriasis\(^2\): 13.2
  - Other dermatology: 6.1
  - Atopic dermatitis: 1.2

**2024 global dermatology market\(^1\)**

- US$43bn sales
  - Acne: 2.1
  - Psoriasis\(^2\): 21.6
  - Other dermatology: 12.3
  - Atopic dermatitis: 7.0

---

1. Evaluate Pharma
2. Growth driven by Biologics
## Rapidly advancing pipeline targeting large and growing markets

Phase 2 trial completions for acne and atopic dermatitis trial and Phase 1b MOA study due for completion in 2019

<table>
<thead>
<tr>
<th>Product candidate</th>
<th>Indication</th>
<th>Pre-clin</th>
<th>Ph 1</th>
<th>Ph 1b</th>
<th>Ph 2</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTX 1503</td>
<td>Moderate to severe acne</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Study complete 3Q 2019</td>
</tr>
<tr>
<td>BTX 1204</td>
<td>Moderate atopic dermatitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Study complete 4Q 2019</td>
</tr>
<tr>
<td>BTX 1308</td>
<td>Psoriasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Study complete 2Q 2019</td>
</tr>
<tr>
<td>BTX 1801</td>
<td>Antimicrobial skin infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Preparing for Phase 1b/2 study</td>
</tr>
</tbody>
</table>

**Synthetic CBD with Permetrex™ technology**

**Permetrex™ programs**

External Various Ongoing collaborations with partners
Overview Permetrex™ Technology
Permetrex™ - proprietary novel skin delivery technology

Makes new types of gels, that deliver very high doses of drug into the layers of the skin without using permeation enhancers, preservatives, or irritating levels of alcohol / petrolatum additives

Initial application

CBD drug is encapsulated in Permetrex™ gel formulation which spreads easily over skin surface

Evaporation of solvent

Volatile parts of the formulation evaporate - leaving a highly concentrated solution of drug on skin surface

Delivery into the skin

The rapid change in concentration of the drug as a result of evaporation, drives quickly CBD into the skin
Permetrex™ delivers 3-5 times more CBD into the skin

BTX 1503 (acne) significantly outperformed the other tested CBD products in delivering drug to the targeted layers of the skin\(^1\)

Relative to the closest comparator, BTX 1503 delivers significantly more CBD to the skin than other OTC creams and gels

1. For further details on these tests – see BOT ASX release on 26/02/19. Skin penetration tested using franz cell human skin vessel with receiver fluid assayed for CBD content at each level (epidermis and dermis). Study conducted by Tioga Research. Botanix data on file.
Over-the-counter CBD products are not what they seem

Over-the-counter (OTC) or internet purchased CBD products often contain approximately one tenth of labelled CBD content, are not regulated and may come with other quality risks¹

<table>
<thead>
<tr>
<th>Product name</th>
<th>Manufacturer</th>
<th>Product type</th>
<th>Label claim CBD content (mg/tube)</th>
<th>Tested CBD content</th>
</tr>
</thead>
<tbody>
<tr>
<td>TheraGreen™</td>
<td>Green Roads</td>
<td>Cream</td>
<td>300</td>
<td>24.5</td>
</tr>
<tr>
<td>Biotech Pain Relief</td>
<td>Medix CBD</td>
<td>Cream</td>
<td>150</td>
<td>11.2</td>
</tr>
<tr>
<td>Therapy+Hemp Cream</td>
<td>Highland Pharms</td>
<td>Cream</td>
<td>200</td>
<td>24.6</td>
</tr>
<tr>
<td>CBD Herbal Repair Cream</td>
<td>MGC Derma</td>
<td>Cream</td>
<td>Undisclosed</td>
<td>8.8</td>
</tr>
<tr>
<td>CBDMEDIC™ Back and Neck</td>
<td>CBDMEDIC</td>
<td>Ointment</td>
<td>Undisclosed</td>
<td>14.9</td>
</tr>
</tbody>
</table>

¹ For further details on these tests – see BOT ASX release on 26/02/19. Products purchased from internet websites of respective vendors and tested by independent laboratory testing service Tioga Research. HPLC analysis of CBD content compared labeled CBD or cannabinoid content to Tioga test results. Botanix data on file.

² Dr Amy Abernethy Twitter post during FDA Public Hearing “Scientific Data and Information about Products Containing Cannabis or Cannabis Derived Compounds” – 31 May 2019

Dr. Amy Abernethy 📤 @DrAbernethyFDA · 22h
Key questions about product safety need to be addressed. Data are needed to determine safety thresholds for CBD; datasets/information should be objective, of adequate quality and available for transparent review. Lab testing and data analyses need to be replicable.
Botanix Dermatology
Development Programs

1. BTX 1503: acne
2. BTX 1204: atopic dermatitis
3. BTX 1308: psoriasis
4. BTX 1801: antimicrobial
1. BTX 1503 – moderate to severe acne

BTX 1503 is a safe and well tolerated topical treatment that potentially addresses all of the 3 causes of acne

BTX 1503 potentially addresses 3 key acne pathologies

1. Exert anti-inflammatory effects via inhibition of the NF-κB pathway and to suppress sebocyte proliferation
2. Have potent anti-microbial activity against gram-positive bacteria
3. Inhibit human keratinocyte proliferation, through a non CB1/CB2 mediated mechanism

---

1. Rocha & Bagatin Acne Vulgaris: an Inflammatory Disease Even Before the Onset of Clinical Lesions (2014). Inflammation and Allergy – Drug Targets June 13(3);
Botanix’s acne target market share exceeds US$1.5bn p.a.

Competitive products with less ideal safety profiles and potentially poorer efficacy generate more than US$1.5bn per annum between them in revenue.

### Top oral brands

<table>
<thead>
<tr>
<th>Rank</th>
<th>Brands</th>
<th>Revenue (US$m)</th>
<th>Scripts ('000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SOLODYN Minocycline, Valeant</td>
<td>$492</td>
<td>434</td>
</tr>
<tr>
<td>2</td>
<td>ACTICLATE Doxycycline, Almirall</td>
<td>$234</td>
<td>261</td>
</tr>
<tr>
<td>3</td>
<td>DORYX FRANCHISE Doxycycline, Mayne</td>
<td>$65</td>
<td>132</td>
</tr>
<tr>
<td>4</td>
<td>TARGADOX Doxycycline, Journey</td>
<td>$40</td>
<td>63</td>
</tr>
</tbody>
</table>

### Top topical brands

<table>
<thead>
<tr>
<th>Rank</th>
<th>Brands</th>
<th>Revenue (US$m)</th>
<th>Scripts ('000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>EPIDUO FRANCHISE Adapalene+BPO, Galderma</td>
<td>$659</td>
<td>1,431</td>
</tr>
<tr>
<td>2</td>
<td>ACZONE FRANCHISE Dapsone, Allergan</td>
<td>$298</td>
<td>625</td>
</tr>
<tr>
<td>3</td>
<td>RETIN-A FRANCHISE Tretinoin, Valeant</td>
<td>$219</td>
<td>304</td>
</tr>
<tr>
<td>4</td>
<td>ONEXTON/ACANYA Clindamycin+BPO, Valeant</td>
<td>$200</td>
<td>410</td>
</tr>
<tr>
<td>5</td>
<td>VELTIN Clindamycin+tretinoin, Almirall</td>
<td>$79</td>
<td>151</td>
</tr>
</tbody>
</table>

Source: Symphony Health Solutions PHAST (accessed 1.2018)

1. US $ represent SHS metric (TRx MBS) or dollarized prescriptions
2. Market shares of the oral branded prescription acne drug market and the topical branded prescription acne drug market according to the total number of prescriptions
Phase 1b patient data for BTX 1503 (acne)

4 week Phase 1b study data shows a marked reduction in inflammatory lesions and no serious adverse events

Lesion count reduction (%) ¹

<table>
<thead>
<tr>
<th>Product</th>
<th>Owner</th>
<th>Lesion count reduction (%)³</th>
<th>2017 annual revenue⁴</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epiduo*</td>
<td>Galderma</td>
<td>~42%</td>
<td>US$659m</td>
</tr>
<tr>
<td></td>
<td></td>
<td>✓ Combination of two drugs – benzoyl peroxide and adapalene</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>✗ Common side effects include redness, skin peeling mild burning / stinging and dryness</td>
<td></td>
</tr>
<tr>
<td>Aczone*</td>
<td>Allergan</td>
<td>~38%</td>
<td>US$298m</td>
</tr>
<tr>
<td></td>
<td></td>
<td>✓ Few side effects</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>✗ Studies showed large placebo / vehicle effect – i.e. at 12 weeks Aczone reduced inflammatory lesions by 54% while vehicle achieved 48% reduction</td>
<td></td>
</tr>
<tr>
<td>BTX 1503</td>
<td>Botanix</td>
<td>~47%</td>
<td>US$ -</td>
</tr>
</tbody>
</table>

1. Botanix BTX.2017.002 trial - Botanix data on file
3. Lesion count reduction based on average inflammatory lesion reduction at 4 weeks
4. Symphony Health solutions PHAST 2018

* Day 35 results indicates the reduction effect persists 7 days after the last treatment.

Day 28 | Day 35

Inflammatory lesions: (47.0%) | Non-inflammatory lesions: (45.0%)
BTX 1503 (acne) - anti-inflammatory effects of CBD

Canfield RBX® images from the Phase 1b acne patient study, demonstrate a clear anti-inflammatory effect over the 4-week treatment course\(^1\)

1. Botanix Pharmaceuticals data on file – VISIA Complexion Analysis System – Canfield Imaging Systems
**BTX 1503: acne – Phase 2 study well advanced**

12-week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1503 in patients with moderate to severe acne

### Design
- 5 dose groups: ~360 subjects
  - High Dose twice a day: ~90 subjects
  - High Dose once a day: ~90 subjects
  - Low Dose once a day: ~90 subjects
  - Vehicle/Control: ~90 subjects
- ~28 US and Australian dermatology sites
- Children (> 12 years) and adults
- Moderate to severe acne patients
- Treatment Period 12 weeks

### Endpoints
- **Primary endpoints:**
  - Absolute change from Baseline to Week 12 in inflammatory lesions
- **Secondary endpoints:**
  - Absolute change from Baseline to Week 12 in non-inflammatory lesions
  - % change from Baseline to Week 12 in inflammatory and non-inflammatory lesions
  - Proportion of patients with at least 2 grade reduction from Baseline IGA at week 12
- **Safety**
  - Adverse events and local tolerability

---

**Study completion end 3Q CY2019**
Recruitment is complete with final subjects completing in-life phase of study

- No serious adverse events / issues arising from treated patients to date
- Positive feedback from dermatologists on study

BTX 1503 indicative clinical timeline (CY)

<table>
<thead>
<tr>
<th>Event</th>
<th>4Q 2018</th>
<th>1Q 2019</th>
<th>2Q 2019</th>
<th>3Q 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>US sites activated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recruitment peak</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient enrolment complete</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study completion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Atopic dermatitis is a T-cell mediated inflammatory disease of the skin

2. BTX 1204: moderate atopic dermatitis

Atopic dermatitis is a T-cell mediated inflammatory disease of the skin

1. During the “acute phase”, dendritic cells cause excessive Th2 and Th17 cell activation
2. During the “chronic phase”, dendritic cells recruit Th1 cell populations that release Interferon-g

Cannabidiol inhibits **Th17 responses** (IL17), anti-inflammatory effect (in vitro model of IL-17A-induced mucosal inflammation using human cells\(^1,2\))

Cannabidiol attenuates **Th2 responses** (IL4/IL13), anti-inflammatory effect (in mouse models of AD\(^3,4\))

Cannabidiol inhibits **Interferon-g production** which prevents deterioration of skin barrier function (in activated lymphocyte cultures\(^1\) and mouse model of autoimmune myocarditis\(^5\))

---

1. Harvey et al. Cytokine. 2014;65:236-244
Atopic dermatitis market projected to be ~US$25bn in 2027

BTX 1204 addresses the need for a safe, non-steroid topical option for chronic use with multiple mechanisms of action including anti-inflammatory, anti-microbial and immune modulating

One of the most common skin diseases

- 2% - 3% of adults, 25% of children
- 75% of patients are moderate to severe

Large unmet needs across the atopic dermatitis population

- Few safe and effective non-steroidal option for chronic use
- Biologics address only the severe population

Pediatric population particularly has a need for a steroid free alternative

- Safety concerns with steroids are high
- Topical Calcineurin Inhibitors (Protopic/Elidel) have a boxed warning
- Current non-steroidal options have been reported to have tolerability concerns

4. Symphony Health Services (PHAST) 2017
BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of atopic dermatitis¹

### Treatment success (%)²

<table>
<thead>
<tr>
<th></th>
<th>Day 8</th>
<th>Day 15</th>
<th>Day 29</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BTX 1204</strong></td>
<td>![Graph Data]</td>
<td>![Graph Data]</td>
<td>![Graph Data]</td>
</tr>
<tr>
<td><strong>Vehicle</strong></td>
<td>![Graph Data]</td>
<td>![Graph Data]</td>
<td>![Graph Data]</td>
</tr>
</tbody>
</table>

#### Phase 1b study results support efficacy and safety potential

- Efficacy still increasing at 4 week timepoint
  - Achieved treatment success similar to many competitive topical products
  - Data suggests longer treatment period for BTX 1204 possible for increased efficacy

- Clear separation from vehicle (placebo)
  - Despite being a small study, BTX 1204 shows superiority over vehicle, starting at early time points

- Excellent safety profile
  - Safety and tolerability established with no burning, stinging or application site adverse events
  - BTX 1204 profile may allow extended dosing which remains a key challenge with most available therapies

---

1. Botanix data on file. Results indicated substantial reduction in key signs of AD, providing confidence that unmet needs in AD can be addressed
2. Treatment success defined as a greater than, or equal to, a 4 point improvement in the signs and symptoms of AD
**BTX 1204: atopic dermatitis – Phase 2 study underway**

12 week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1204 in patients with moderate atopic dermatitis (AD)

**Design**
- 2 dose groups: ~200 subjects
  - BTX 1204: ~100 subjects
  - Vehicle/Control: ~100 subjects
- ~25 US and Australian dermatology sites
- Children (> 12 years) and adults
- Moderate AD patients
- Treatment period of 12 weeks

**Endpoints**
- **Primary endpoint**
  - Proportion of subjects with ISGA success defined as an ISGA score of “Clear” (0) or “Almost Clear” (1) with at least a 2 grade improvement from Baseline at Week 12
- **Secondary endpoints**
  - Change from Baseline in the Signs of AD
  - % body surface area (BSA) affected by AD
  - Time to achieve IGA success
- **Safety**
  - Adverse events and local tolerability

**Study completion 4Q CY2019**
BTX 1204: atopic dermatitis – Phase 2 study advancing

Randomised vehicle controlled study in 200 moderate patients

- Program leverages existing data from BTX 1503 acne studies, lowering regulatory and safety hurdles
- Common DEA licensed dermatology clinics from BTX 1503 acne Phase 2 study, reduces cost and start-up timing

**BTX 1204 indicative clinical timeline (CY)**

- AU sites activated
- US sites activated
- Recruitment peak
- Patient enrolment complete
- Study completion

<table>
<thead>
<tr>
<th>Event</th>
<th>Quarter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recruitment peak</td>
<td>4Q 2018</td>
</tr>
<tr>
<td>Patient enrolment complete</td>
<td>1Q 2019</td>
</tr>
<tr>
<td>Study completion</td>
<td>3Q 2019</td>
</tr>
<tr>
<td>AU sites activated</td>
<td>2Q 2019</td>
</tr>
<tr>
<td>US sites activated</td>
<td>4Q 2019</td>
</tr>
</tbody>
</table>
3. BTX 1308 for psoriasis

Phase 1b patient study is testing BTX 1308 in a model that allows biopsies to be collected which may help validate the mechanism of action of cannabidiol in psoriasis.

**Psoriasis plaque model**

*Novel multi-drug comparison study format*

- Biopsies of each drug zone and also healthy skin data may help elucidate the mechanism of action
- Potentially provides insight into pathways and gene targets of interest

**BTX 1308 indicative clinical timeline (CY)**

- **Study commencement**: 4Q 2018
- **Patient enrolment completed**: 1Q 2019
- **Study completion**: 2Q 2019
4. **BTX 1801: novel antimicrobial for serious skin diseases**

Natural potential of cannabinoids is enhanced by delivery with Permetrex™ technology

Minimum Inhibitory Concentration (MIC) effect of BTX 1801 against industry standard antibiotics

![Image showing MIC effect of BTX 1801 compared to Vancomycin and Mupirocin]

**BTX 1801 may have the following benefits:**

- Gram-positive bactericidal effect
- Active against MRSA
- Topical application suited for skin infections
- Benign side effect profile based on previous clinical studies
- Ability to use long term
- Anti-inflammatory and skin barrier improvement properties
- Prevent early use of IV antibiotics (significant side effects)

**Note:** the lower the MIC – the more effective the drug is at killing the target bacteria and the less drug is required to have the desired effect

---

1. Vancomycin used to treat serious infections in many different parts of the body while Mupirocin used to treat certain skin infections
2. Potential benefits based on published literature and independent testing by third party laboratories Botanix data on file
The market for skin infection drugs continues to increase with the challenges of resistance driving the price of more effective products higher.

**Skin infection drugs market forecast 2014-2025 (US$m)**

- Skin infections are the most common healthcare-associated infection (HAIs) accounting for 31% of all HAIs among hospitalised patients.
- MRSA accounts for ~59% of skin & soft tissue infections (SSTIs) presenting to the ER.
- Patients with HAI’s face prolonged hospital stays, treatment-associated risks, long-term adverse outcomes and a 2–11 fold increase in mortality risks.

Source: Visiongain 2015 Dermatological Drugs Market Forecast 2014-2025
## Botanix leads the way in synthetic CBD clinical development

Phase 2 acne trial completion in 3Q and phase 2 atopic dermatitis trial completion in 4Q 2019

<table>
<thead>
<tr>
<th>Product candidate</th>
<th>Indication</th>
<th>Pre-clin</th>
<th>Ph 1</th>
<th>Ph 1b</th>
<th>Ph 2</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTX 1503</td>
<td>Moderate to severe acne</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Study complete 3Q 2019</td>
</tr>
<tr>
<td>BTX 1204</td>
<td>Moderate atopic dermatitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Study complete 4Q 2019</td>
</tr>
<tr>
<td>BTX 1308</td>
<td>Psoriasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Study complete 2Q 2019</td>
</tr>
<tr>
<td>BTX 1801</td>
<td>Antimicrobial skin infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Preparing for Phase 1b/2 study</td>
</tr>
</tbody>
</table>

### Synthetic CBD with Permetrex™ technology

### Permetrex™ programs

| External | Various                      |          |      |       |         | Ongoing collaborations with partners |

**Botanix Overview – June 2019**

**www.botanixpharma.com**
Disclaimer

This presentation prepared by Botanix Pharmaceuticals Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.
Contact us

Matt Callahan
Botanix Pharmaceuticals
Founder and Board Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com

Visit us
www.botanixpharma.com

Follow us on social media

Botanix Pharmaceuticals Limited (ASX:BOT)